Healthy Skepticism Library
Items published in 2004
There are 870 items in the Healthy Skepticism Library that were published in 2004.
Page 9 of 9 pages ‹ First < 7 8 9
HSL9743
Alam MM.
We should give manufacturers the benefit of the doubt [10]
Pharmaceutical Journal 2004; 272:(7289):281
HSL9744
Astbury FG, Mahaffy PJ.
Managing the risk of thalidomide (multiple letters)
Pharmaceutical Journal 2004; 272:(7289):278-279
HSL9745
Kirby PM.
Back to the dark ages
Pharmaceutical Journal 2004; 272:(7287):215
HSL9746
Pfizer helps pharmacists capitalise on health care market
Pharmaceutical Journal 2004; 272:(7287):209
HSL9752
Wechsler J.
Pharmaceutical Pricing and Healthcare Access: Lead Policy Agenda
Pharmaceutical Technology 2004; 28:(3):26-34
HSL9754
Government looks at instalment dispensing for benzodiazepines
Pharmaceutical Journal 2004; 272:(7288):238
HSL9755
Harris KM, Devries A, Dimidjian K.
Trends in Naltrexone Use among Members of a Large Private Health Plan
Psychiatric Services 2004; 55:(3):221
HSL9756
Tawab M.
Viagra from the Internet
Pharmazeutische Zeitung 2004; 149:(9):43
HSL9757
Hollon MF.
Direct-to-consumer marketing of prescription drugs: a current perspective for neurologists and psychiatrists.
CNS Drugs 2004; 18:(2):69-77
HSL9758
Thomson D, Capstick T.
How a risk management programme can ensure safety in thalidomide use
Pharmaceutical Journal 2004; 272:(7286):190-191
HSL9760
Valaitis J, Peterson T.
Ethical Dilemmas: Scenario 3
Wisconsin Medical Journal 2004; 103:(1):11-12
HSL9761
Bellingham C.
How to improve contraception services
Pharmaceutical Journal 2004; 272:(7285):149-150
HSL9762
Patients should be able to buy Tamiflu, according to NPA
Pharmaceutical Journal 2004; 272:(7285):146
HSL9764
Foran TM.
Choices in hormonal contraception
Medicine Today 2004; 5:(2):30-37
HSL9765
Goldenberg MM.
Medicare and the New Generic Drug Legislation
P and T 2004; 29:(2):89-94
HSL9767
Parvez N, Ahmed T, Monif T, Saha N, Sharma PL.
Comparative bioavailability of three oral formulations of sustained release theophylline in healthy human subjects
Indian Journal of Pharmacology 2004; 36:(1):29-33
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=36&issue=1&spage=29
HSL9769
Law and ethics bulletin
Pharmaceutical-Journal 2004; 272:(7282):70
HSL9770
Medicine adverts appeals process clarified
Pharmaceutical Journal 2004; 272:(7282):48
HSL9771
European reforms will speed up access to new drugs
Pharmaceutical Journal 2004; 272:(7282):47
HSL9772
Guidance for brand name prescriptions updated
Pharmaceutical Journal 2004; 272:(7282):46
HSL9773
Preedy V, Mantle D.
Adverse effect on coenzyme Q10 levels [2]
Pharmaceutical Journal 2004; 272:(7281):13
HSL9774
Bellingham C.
Is pharmacy ready for OTC statins?
Pharmaceutical Journal 2004; 272:(7281):8-9
HSL9775
Spending rates for dementia drugs still vary
Pharmaceutical Journal 2004; 272:(7281):
HSL9776
'Medicamentation' of society: An example of social pharmacology
Prescrire International 2004; 13:(69):38
HSL9778
Lexchin J.
Are new drugs as good as they claim to be?
Australian Prescriber 2004; 27:(1):2-3
HSL9782
Luggen ME.
Trials Are Short, Disease Long: Measuring Drug Utility Beyond Clinical Trials
Journal of Rheumatology 2004; 31:(2):205-6
HSL9785
O'Connell B.
Going off Patent: Standing Pat or Getting Out
BioPharm International 2004; 17:(1):26, 28
HSL9786
Wechsler J.
Medicare Bill Boosts Coverage for Biotech Therapies
BioPharm International 2004; 17:(1):20, 22
HSL9788
Huang SM, Hall SD, Watkins P, Love LA, Serabjit-singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD.
Drug interactions with herbal products and grapefruit juice: A conference report
Clinical Pharmacology and Therapeutics 2004; 71:(1):1-12
http://ezproxy.library.uq.edu.au/login?url=http://dx.doi.org/10.1016/j.clpt.2003.07.002
HSL9791
Barlas S.
Major Changes Ahead: Medicare Drug Benefit to Affect the Entire Drug-Distribution Chain
P and T 2004; 29:(1):13
HSL9792
Nash DB.
Countering Counterfeiters
P and T 2004; 29:(1):10-11
HSL9875
Pursuing a career in medical sales
Nature Reviews Drug Discovery 2004; 3:(1):97-98
HSL9877
Circles to square on medicines
Veterinary Record 2004; 154:(2):33
HSL9878
Calaf J, Ferrer M.
Pharmacological treatment of menopause in Spain in 2002
Clinica e Investigacion en Ginecologia y Obstetricia 2004; 30:(9):299-306
HSL11251
Medawar C, Herxheimer A.
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
The International Journal of Risk and Safety in Medicine 2004; 16:(1):5-19
http://iospress.metapress.com/app/home/contribution.asp?referrer=parent&backto=issue,3,8;journal,12,26;linkingpublicationresults,1:103162,1;
HSL11531
DiMasi JA, Paquette C.
The economics of follow-on drug research and development: trends in entry rates and the timing of development.
Pharmacoeconomics 2004; 22:((2 Suppl 2)):1-14.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15660473
HSL11562
Grabowski H.
Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures
Pharmacoeconomics 2004; 22:((2 Suppl 2)):15-24.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=15660474
HSL12480
Phillips BJ, McQuarrie EF.
Beyond Visual Metaphor: A New Typology of Visual Rhetoric in Advertising
Marketing Theory 2004; 4:(1-2):113-136
http://mtq.sagepub.com/cgi/content/abstract/4/1-2/113?ck=nck
HSL13552
von Hippel A
Better Health Care At Half The Cost
: Xlibris Corporation 2004
http://www2.xlibris.com/bookstore/bookdisplay.asp?bookid=24928
HSL14879
Ashcroft RE.
Current epistemological problems in evidence based medicine.
J Med Ethics 2004; 30:131–135
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1733829&blobtype=pdf
HSL15098
Rasmussen N.
The Moral Economy of the Drug Company–Medical Scientist Collaboration in Interwar America
Social Studies of Science 2004; 34:(2):161-185
http://sss.sagepub.com/cgi/content/abstract/34/2/161
HSL15100
Healy D.
Shaping the Intimate:: Influences on the Experience of Everyday Nerves
Social Studies of Science 2004; 34:(2):219-245
http://sss.sagepub.com/cgi/content/abstract/34/2/219
HSL15542
Quick J, Dé A.
Update to the Direct-to-Consumer Debate: The Risks and Benefits of Pharmaceutical Promotion Across the Atlantic
Public Relations Strategist 2004; 10:(2):29-31
http://www.prsa.org/publications/strategist/
HSL16338
Even P, Debré B
Savoir et Pouvoirs Paris: Le Cherche Midi 2004
http://www.eyrolles.com/Entreprise/Livre/savoirs-et-pouvoirs-9782749102498
HSL16341
Hadler N
The Last Well Person: How to stay well despite the health-care system. Montreal-Kingston: McGill-Queens University Press 2004
http://books.google.com.au/books?id=kTjV7urN8h8C&dq=Hadler,+Nortin.+The+Last+Well+Person:+How+to+stay+well+despite+the+health-care+system.&source=gbs_navlinks_s
HSL16346
Medawar C, Hardon A
Medicines out of Control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant 2004
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1079538
HSL16349
Saint-Onge JC
L’envers de la pilule: Les dessous de l’industrie pharmaceutique. Montréal: õcosociété 2004
http://www.livresquebecois.com/livre.asp?id=pzobfyugobfug&/l-envers-de-la-pilule-nouvelle-edition/jean-claude-st-onge
HSL16524
Kaiser T, Ewers H, Waltering A, Beckwermert D, Jennen C, Sawicki PT
Sind die Aussagen medizinischer Werbeprospekte korrekt?
Arznei Telegramm 2004; 35:(21):3
www.di-em.de/data/at_2004_35_21.pdf
HSL16528
Huff-Rousselle M.
Book review: How to Develop and Implement a National Drug Policy.
Int J Health Plann Mgmt 2004; 19:1–2
HSL16798
Glass HE.
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?
Dis Manag 2004 Spr; 7:(1):77-87
http://www.liebertonline.com/doi/abs/10.1089/109350704322919014
HSL18036
Collier J
Regulating the regulators
Lancet 2004; 363:(9427):2199-2199
http://linkinghub.elsevier.com/retrieve/pii/S014067360416529X
HSL18038
Spurgeon D
US junior doctors found to be ignorant of drug companies' tactics
BMJ 2004; 328:(7447):1032
http://www.bmj.com/cgi/content/full/328/7447/1032-a
HSL18039
Harvey K
Website review: AdWatch web site
Aust Prescr 2004; 27:(3):63
http://www.australianprescriber.com/index.php?content=/agazines/vol27no3/63_websitereview.htm
HSL18177
Fava GA
Conflict of Interest in Psychopharmacology: Can Dr. Jekyll Still Control Mr. Hyde?
Psychother Psychosom 2004; 73:1-4
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000074433
HSL19046
Caudill-Slosberg MA, Schwartz LM, Woloshin S
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs.2000.
Pain 2004; 109:(3):514-9
http://www.painjournalonline.com/article/S0304-3959(04)00130-7/abstract
HSL19387
Donohue JM, Berndt ER
Effects of direct-to-consumer advertising on medication choice: the case of anti-depressants
Journal of Public Policy & Marketing 2004; 23:(2):115-127
http://www.kff.org/rxdrugs/upload/Effects-of-Direct-to-Consumer-Advertising-on-Medication-Choice-the-Case-of-Antidepressants.pdf
HSL19390
Manchanda P, Rossi P, Chintagunta P
Response modeling with nonrandom marketing-mix variables
J Marketing Res 2004; 41:467–478
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=371360
HSL19286
Vadodara/ Bilaspur
Impoverishing the Poor: Pharmaceuticals and Drug Pricing in India : LOCOST/JSS 20040
http://www.scribd.com/my_document_collections/2879052
HSL19511
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one US medical school
Academic Medicine 2004; 79:(11):1041-5
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=NxpFhX0RqlgMjcQZTwGJ3ngkLPpGZCNQPXqnKHLKYpXzVqQGgyhh!1776764395!181195628!8091!-1?issn=1040-2446&volume=79&issue=11&spage=1041
HSL19515
Light D, Lexchin J
Will lower drug prices jeoparidize drug research? A policy fact sheet
The American Journal of Bioethics 2004; 4:(1):
http://bioethics.net/journal/j_articles.php?aid=61
HSL16352
Welch G
Should I be tested for cancer. Maybe Not and Here’s Why. Berkley and Los Angeles: University of California Press 2004
http://books.google.com.au/books?id=SAXl2PASXNkC&dq=Welch,+Gilbert.+Should+I+be+tested+for+cancer.+Maybe+Not+and+Here’s+Why.&printsec=frontcover&source=bn&hl=en&ei=DrKYSvWeNJODkAWquqyrAg&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false
HSL19739
Manchanda P, Wittink Dr, Ching A, Cleanthous P, Ding M, Dong XJ, Leeflang PSH, Misra S, Mizik N, Narayanan S, Steenburgh T, Wieringa JE, Wosinska M, Xie Y,
Understanding Firm, Physician and Consumer Choice Behaviour in the Health Care Industry
Sixth Invitational Choice Symposium hosted by the University of Colorado 2004 Sep
www.springerlink.com/index/518wvx08320847g5.pdf
HSL19752
Flower R.
Lifestyle drugs: pharmacology and the social agenda.
Trends Pharmacol Sci 2004; 25:(4):182-5
http://www.sciencedirect.com/science/article/pii/S0165614704000549
HSL19832
AMSA move on code
Australian Medicine 2004 May 174
HSL19847
Taylor B.
Giveaway drugs: good intentions, bad design.
Health Aff (Millwood) 2004; 23:(1):213-7
http://content.healthaffairs.org/content/23/1/213.long
HSL19850
Finaly L
Just Like a Woman
Fashion Date uncertain 200477-78
Page 9 of 9 pages ‹ First < 7 8 9
